BACKGROUND: Mediastinal radiation can accelerate atherosclerosis in Hodgkin lymphoma survivors (HLS), and early detection is optimal. Peripheral arterial tonometry (PAT), a non-invasive measure of endothelial function, is a surrogate marker of sub-clinical atherosclerosis. The objective of our study was to evaluate endothelial function in HLS and controls using PAT and to determine the influence of mediastinal radiation. PROCEDURE: Cross-sectional evaluation was performed on 26 HLS aged 12-30 years who were a minimum of 2 years from therapy, and their healthy age and gender matched controls. Evaluation included assessment for cardiovascular risk factors and completion of the Habitual Activity Estimation Score (HAES) questionnaire to assess activity level. Endothelial Function was measured using PAT hyperemia ratios (PAT-HR). RESULTS: HLS and controls were similar for baseline variables (mean age 23.3 +/- 5 yrs vs. 23.4 +/- 4.8 yrs, p = 0.92). HLS were on average 6.7 +/- 4.6 yrs post treatment. No differences in endothelial function or cardiovascular risk factors were observed between HLS and controls. However, impaired endothelial function, as evidenced by lower PAT-HR (1.67 +/- 0.39 vs. 2.03 +/- 0.37, p < 0.01) was seen in HLS (n = 13) who received mediastinal radiation (mean radiation dose 2,600 +/- 840 cGy) compared to controls. CONCLUSIONS: Impaired endothelial function was preferentially observed in HLS who received mediastinal radiation, while no difference was observed between the HLS and control groups overall. This finding, assessed using a non invasive test of endothelial function, confirms that mediastinal radiation is an additional cardiovascular risk factor in this young cohort of patients. Further studies of endothelial function in this patient population are warranted.
BACKGROUND: Mediastinal radiation can accelerate atherosclerosis in Hodgkin lymphoma survivors (HLS), and early detection is optimal. Peripheral arterial tonometry (PAT), a non-invasive measure of endothelial function, is a surrogate marker of sub-clinical atherosclerosis. The objective of our study was to evaluate endothelial function in HLS and controls using PAT and to determine the influence of mediastinal radiation. PROCEDURE: Cross-sectional evaluation was performed on 26 HLS aged 12-30 years who were a minimum of 2 years from therapy, and their healthy age and gender matched controls. Evaluation included assessment for cardiovascular risk factors and completion of the Habitual Activity Estimation Score (HAES) questionnaire to assess activity level. Endothelial Function was measured using PAT hyperemia ratios (PAT-HR). RESULTS: HLS and controls were similar for baseline variables (mean age 23.3 +/- 5 yrs vs. 23.4 +/- 4.8 yrs, p = 0.92). HLS were on average 6.7 +/- 4.6 yrs post treatment. No differences in endothelial function or cardiovascular risk factors were observed between HLS and controls. However, impaired endothelial function, as evidenced by lower PAT-HR (1.67 +/- 0.39 vs. 2.03 +/- 0.37, p < 0.01) was seen in HLS (n = 13) who received mediastinal radiation (mean radiation dose 2,600 +/- 840 cGy) compared to controls. CONCLUSIONS: Impaired endothelial function was preferentially observed in HLS who received mediastinal radiation, while no difference was observed between the HLS and control groups overall. This finding, assessed using a non invasive test of endothelial function, confirms that mediastinal radiation is an additional cardiovascular risk factor in this young cohort of patients. Further studies of endothelial function in this patient population are warranted.
Authors: Elif Seda Selamet Tierney; Jane W Newburger; Kimberlee Gauvreau; Judith Geva; Elizabeth Coogan; Steven D Colan; Sarah D de Ferranti Journal: J Pediatr Date: 2009-02-12 Impact factor: 4.406
Authors: V King; L S Constine; D Clark; R G Schwartz; A G Muhs; M Henzler; A Hutson; P Rubin Journal: Int J Radiat Oncol Biol Phys Date: 1996-11-01 Impact factor: 7.038
Authors: J T Kuvin; A R Patel; K A Sliney; N G Pandian; W M Rand; J E Udelson; R H Karas Journal: J Am Coll Cardiol Date: 2001-12 Impact factor: 24.094
Authors: Paul A Heidenreich; Steven L Hancock; Byron K Lee; Carol S Mariscal; Ingela Schnittger Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield Journal: Lancet Date: 1992-11-07 Impact factor: 79.321
Authors: Jeffrey T Kuvin; Ayan R Patel; Kathleen A Sliney; Natesa G Pandian; Jacob Sheffy; Robert P Schnall; Richard H Karas; James E Udelson Journal: Am Heart J Date: 2003-07 Impact factor: 4.749
Authors: Piero O Bonetti; Gregory W Barsness; Paul C Keelan; Theresa I Schnell; Geralyn M Pumper; Jeffrey T Kuvin; Robert P Schnall; David R Holmes; Stuart T Higano; Amir Lerman Journal: J Am Coll Cardiol Date: 2003-05-21 Impact factor: 24.094
Authors: Cindy K Blair; Aaron S Kelly; Julia Steinberger; Lynn E Eberly; Char Napurski; Kim Robien; Joseph P Neglia; Daniel A Mulrooney; Julie A Ross Journal: Pediatr Blood Cancer Date: 2014-08-30 Impact factor: 3.167
Authors: Andreas Daiber; Sebastian Steven; Alina Weber; Vladimir V Shuvaev; Vladimir R Muzykantov; Ismail Laher; Huige Li; Santiago Lamas; Thomas Münzel Journal: Br J Pharmacol Date: 2016-07-04 Impact factor: 8.739